For the third quarter of fiscal year ending March 2026, consolidated net sales were 98,857 million yen (0.5% year-over-year decrease), operating income was 16,400 million yen (5.7% year-over-year decrease), and net income attributable to owners of the parent was 11,726 million yen (5.2% year-over-year decrease).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6960","jir_company_name":"Fukuda Denshi Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/6960-20260126-01.pdf","jir_short_summary":"For the third quarter of fiscal year ending March 2026, consolidated net sales were 98,857 million yen (0.5% year-over-year decrease), operating income was 16,400 million yen (5.7% year-over-year decrease), and net income attributable to owners of the parent was 11,726 million yen (5.2% year-over-year decrease).","jir_summary":"### Overview of Business Performance\nFor the third quarter of the fiscal year ending March 2026, consolidated financial results showed net sales of 98,857 million yen (0.5% year-over-year decrease), operating income of 16,400 million yen (5.7% year-over-year decrease), ordinary income of 16,762 million yen (6.8% year-over-year decrease), and net income attributable to owners of the parent of 11,726 million yen (5.2% year-over-year decrease). By segment, net sales decreased in the Clinical Examination Equipment and Patient Monitoring Equipment segments, while the Therapeutic Equipment and Consumables segments recorded increases. Despite addressing market conditions influenced by Medical DX promotion and regional medical care initiatives, a declining trend was observed on the profit side.\n\n### Financial Position and Dividend Status\nTotal assets decreased by 5,353 million yen from the end of the previous consolidated fiscal year to 215,968 million yen, liabilities decreased by 5,234 million yen to 34,434 million yen, and net assets decreased by 118 million yen to 181,533 million yen. The amount of treasury stock has increased due to share buybacks. The annual dividend forecast for the fiscal year ending March 2026 is 180 yen (90 yen interim and 90 yen year-end), maintaining the same level as the previous fiscal year. There is no revision to the earnings forecast, and while remaining cautious about the uncertain economic environment, results are expected to proceed roughly as forecasted.","jir_financial_highlights":"Net Sales: 98,857 million yen (0.5% year-over-year decrease)\nOperating Income: 16,400 million yen (5.7% year-over-year decrease)\nOrdinary Income: 16,762 million yen (6.8% year-over-year decrease)\nNet Income Attributable to Owners of Parent: 11,726 million yen (5.2% year-over-year decrease)\nTotal Assets: 215,968 million yen (Decrease of 5,353 million yen from previous fiscal year-end)\nNet Assets: 181,533 million yen (Decrease of 118 million yen from previous fiscal year-end)\nTreasury Stock Shares: 10,443,285 shares (Increase year-over-year)\nAnnual Dividend (Forecast): 180 yen (90 yen x 2 times) (Increase compared to previous period)","jir_category":"","jir_hashtags":"#FukudaDenshiCoLtd, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: 98,857 million yen (0.5% year-over-year decrease)\nOperating Income: 16,400 million yen (5.7% year-over-year decrease)\nNet Income Attributable to Owners of Parent: 11,726 million yen (5.2% year-over-year decrease)","jir_meta_title":"Fukuda Denshi Co., Ltd. FY March 2026 Q3 Financial Summary Net Sales 98.857 billion yen, Operating Income 16.4 billion yen","jir_meta_description":"Fukuda Denshi Co., Ltd. FY March 2026 Q3 financial summary. Net sales declined 0.5% year-over-year to 98.857 billion yen, operating income fell 5.7% to 16.4 billion yen, and net income attributable to owners of the parent decreased 5.2% to 11.726 billion yen. Dividend forecast maintained at 180 yen.","jir_og_title":"Fukuda Denshi Co., Ltd. Announces FY March 2026 Q3 Financial Summary","jir_og_description":"Net sales: 98.857 billion yen, operating income: 16.4 billion yen, net income: 11.726 billion yen. Revenue and earnings decreased year-over-year, while dividends remain unchanged.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[99395,98857],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[17392,16400],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[12374,11726],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales (Million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Clinical Examination Equipment\\\",\\\"Patient Monitoring Equipment\\\",\\\"Therapeutic Equipment\\\",\\\"Consumables\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY March 2025 Q3\\\",\\\"data\\\":[18955,6749,45820,27871],\\\"backgroundColor\\\":\\\"#76b7b2\\\"},{\\\"label\\\":\\\"FY March 2026 Q3\\\",\\\"data\\\":[16830,5878,47082,29065],\\\"backgroundColor\\\":\\\"#59a14f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"self_stock_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Treasury Stock Shares Trend (Shares)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Treasury Stock Shares\\\",\\\"data\\\":[8918234,10443285],\\\"borderColor\\\":\\\"#edc948\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":8718,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-20897","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n